Prof. Dr. med. et phil. nat. Markus Jörger
chief of service
Medizinische Onkologie und Hämatologie · Dept. I
Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers
Apr 15, 2019Kombination von Nivolumab mit dem anti-IL8 monoklona-len Antikörper BMS-986253 in PatientInnen mit selektierten fortgeschrittenen soliden Malignomen und erhöhten IL-8 Blutspiegeln.
Clinical Studies - Apr 15, 2019 - Dec 31, 2020
Automatically Closed
Project leader: Jörger Markus
A Phase 2, multi-center, open label study of NIR178 in combination with PDR001 in patients with selected ad-vanced solid tumors and non-Hodgkin lymphoma
Oct 5, 2017This is a multi-center, open label, phase 2 study to evaluate efficacy of the NIR178 and PDR001 combination in NSCLC, other solid tumors, and diffuse large B-cell lymphoma (DLBCL). The study has three parts: part 1: Multi-arm Bayesian adaptive signal...
Clinical Studies - Oct 5, 2017 - Feb 20, 2024
Automatically Closed
Project leader: Jörger Markus
SAKK 41/16: Neoadjuvant treatment with Regorafenib and Capecitabine combined with radiotherapy in locally advanced rectal ca cer. A multicenter phase Ib trial (RECAP)
Mar 7, 2017Despite treatment of locally advanced rectal cancer re-lapses are frequent. Several attempts to improve these results with therapy intensification have shown modest effect on disease free survival (DFS) and overall survival (OS). Recent studies with...
Clinical Studies - Mar 7, 2017 - Jul 31, 2019
Automatically Closed
Project leader: Jörger Markus
PhenoTox: Hunting the missing heritability of early-onset fluoropyrimdine-related toxicity in cancer patients: an observational multi-center study
Oct 4, 2016In cancer patients receiving fluoropyrimidine-based chemo-therapy, there is extensive inter-individual variability in plasma drug concentrations and the severity of chemo-therapy-related toxicity. A strong association has been shown for plasma concen...
Clinical Studies - Oct 4, 2016 - Feb 27, 2024
Completed
Project leader: Jörger Markus
An open-label Phase 1/2a study of BAL101553 adminis-tered as 48-hour intravenous infusions in adult patients with advanced solid tumors
Aug 19, 2016The primary objectives of this study are to determine the maximum tolerated dose (MTD) and to characterize dose-limiting toxicities (DLTs) of BAL101553, administered as an intravenous (IV) infusion over 48 hours on study Days 1, 8 and 15 of a 28-day...
Clinical Studies - Aug 19, 2016 - Jan 31, 2018
Automatically Closed
Project leader: Jörger Markus
A Phase 1/2a Dose Escalation and Cohort Expansion Study for Safety, Tolerability, and Efficacy of BMS-986156 Administered Alone and in Combination with Nivolumab (BMS-936558, anti PD-1 Monoclonal Anti-body) in Advanced Solid Tumors
Jul 21, 2016This is a Phase 1/2a, open-label study of BMS-986156 administered as a single agent and in combination with nivolumab in subjects with advanced solid tumors. The study will be conducted in 4 parts. Parts A and B will consist of dose escalation with B...
Clinical Studies - Jul 21, 2016 - Sep 30, 2017
Automatically Closed
Project leader: Jörger Markus
Predictive and prognostic value of integrated exon-level expression to approach drug-response and resistance to EGFR-targeted treatment in non-small cell lung cancer
Jan 1, 2015Activating mutations in lung cancer are targeted by a series of molecularly targeted therapies. Patients harboring such mutations can receive significant benefit from these therapies. However a proportion of patients without activating mutations can...
Fundamental Research - Jan 1, 2015 - Dec 31, 2016
Automatically Closed
Project leader: Baty Florent
Members: Franzini Anca, Früh Martin, Jörger Markus, Brutsche Martin
MP0250; A phase I multi-centre, open-label, repeated-dose, dose-escalation study to assess safety, tolerability and pharmacokinetics of MP0250 in patients with advanced solid tumours
Oct 23, 2014Dies ist die erste Studie zur Anwendung des neuen Medikaments MP0250 am Menschen. Das Hauptziel ist es, dessen Sicherheit und Verträglichkeit bei Krebs-Patienten zu untersuchen. Diese Studie wird auch prüfen, wie das Medikament durch den Körper verä...
Clinical Studies - Oct 23, 2014 - Sep 30, 2016
Automatically Closed
Project leader: Omlin Aurelius
Members: Hess Dagmar, Jörger Markus, Bickel Angelika
Cachexia and Toxicity: cachexia-based dosing vs. standard of care (CAT-Trial)
Jan 23, 2014Cancer cachexia is a frequent condition, characterized by muscle loss not reversible by nutrition only, caused by procatabolic (inflammatory) and hypoanabolic mechanism, with an impact on quality of life, function and survival. An association of musc...
Clinical Studies - Jan 23, 2014 - Nov 30, 2014
Automatically Closed
Project leader: Strasser Florian
Members: Blum David, Jörger Markus, Fornaro Jürgen, Magayakalbermatten N, Behnke Nadine
A Phase Ib/II, open-label, multicenter study of INC280 in combination with buparlisib in adult patients with recurrent glioblastoma
Dec 9, 2013In diese Studie sollen Patienten eingeschlossen werden, die an rezidivierendem Glioblastom leiden. Untersuchungen haben gezeigt, dass bei der Entstehung und Aufrecht-erhaltung des Glioblastoms verschiedene Faktoren wie die Deregulierung der Phosphati...
Clinical Studies - Dec 9, 2013 - Feb 6, 2015
Automatically Closed
Project leader: Jörger Markus
Members: Hundsberger Thomas, Hollenstein Monika, Desax Marie-Claire
A phase III, multicenter, randomized, open-label study of oral LDK378 versus standard chemotherapy in adult patients with ALK-rearranged (ALK-positive) advanced non-small cell lung cancer who have been treated previously with chemotherapy (platinum doublet) and crizotinib
Dec 4, 2013Diese Studie richtet sich an Patienten mit ALK-positivem Nicht-kleinzelligem Lungenkrebs, die mit Platin-basierter Doppelchemotherapie und mit dem ALK-Inhibitor Crizotinib ausbehandelt wurden. Die Therapiemöglichkeiten für diese Gruppe von Patienten...
Clinical Studies - Dec 4, 2013 - Dec 4, 2013
Automatically Closed
Project leader: Früh Martin
Members: Jörger Markus, Siano Marco
LDE225 in combination with Paclitaxel in patients with advanced solid tumors. A multicenter phase I trial
Oct 30, 2013Die Kombination von LDE225 mit Paclitaxel wurde noch nicht getestet und es ist noch nicht bekannt welche Nebenwirkung entstehen können. Man kann noch nicht sicher sagen, dass diese Kombination eine Wirksamkeit bei Patienten mit fortgeschrittenen soli...
Clinical Studies - Oct 30, 2013 - Oct 1, 2015
Automatically Closed
Project leader: Hess Dagmar
Members: Jörger Markus, Omlin Aurelius
ETOP 2-11 (BELIEF) An open-label phase II trial of erlotinib and bevacizumab in pa-tients with advanced non-small cell lung cancer and activating EGFR mutations
Sep 17, 2012Zwar profitieren die meisten Patienten mit fortgeschrittenem Lungenkrebs und aktivierender EGFR Mutation deutlich von einer Monotherapie mit einem EGFR-Inhibitor, leider ist der Therapieeffekt aber von beschränkter Dauer (Median: 9-12 Monate), weil d...
Clinical Studies - Sep 17, 2012 - Sep 27, 2022
Automatically Closed
Project leader: Früh Martin
Members: Siano Marco, Jörger Markus
Serum and tissue biomarkers in patients with early and advanced-stage renal-cell carcinoma
May 1, 2012Das klarzellige Nierenzellkarzinom (kNZK) ist der häufigste Tumorsubtyp beim Nierenkrebs mit der geringsten Überlebensrate. Die Entwicklung von Nachweisverfahren zur Früherkennung von kNZK, und die Identifikation prädiktiver Biomarker in PatientInnen...
Clinical Studies - May 1, 2012 - Jun 30, 2014
Automatically Closed
Project leader: Jörger Markus
Members: Gillessen Sommer Silke, Rothermundt Christian
Circulating micro-RNA profiling in patients with advanced non-squamous non small-cell lung cancer receiving bevacizumab/erlotinib first-line treatment followed by platinum-based chemotherapy at disease progression (SAKK 19/05)
Apr 1, 2012Background: This study was initiated by the Swiss Group for Clinical Cancer Research (SAKK) 19/05 study to assess the predictive and prognostic value of circulating miRNA profiles from peripheral blood of patients with non-squamous non small-cell lu...
Fundamental Research - Apr 1, 2012 - Sep 1, 2013
Completed
Project leader: Brutsche Martin
Members: Jörger Markus, Zappa Francesco, Gautschi Oliver, Pless Miklos, Ochsenbein Adrian, Bubendorf Lukas, von Moos Roger, Betticher Daniel, Stahel Rolph, Früh Martin, Baty Florent
Pharmacogenetics and therapeutic drug monitoring for the optimization of fluoropyrimidine treatment in patients with advanced colorectal cancer (FLOXTOX II)
Feb 1, 2012Es handelt sich um eine prospektive, nicht-randomisierte, pharmakologische Mehrzentrumsstudie. Geeignete PatientInnen werden gefragt, ob sie an der Studie teilnehmen wollen. Nur PatientInnen mit schriftlicher Einwilligung werden in die Studie eingesc...
Clinical Studies - Feb 1, 2012 - Dec 1, 2015
Automatically Closed
Project leader: Jörger Markus
Members: Horber Daniel, Gueller Ulrich
Cytochrom p450 3A4 and 1A2 phenotyping for the individualization of treatment with sunitinib or erlotinib in cancer patients
Jan 15, 2012Die Tyrosinkinaseinhibitoren Sunitinib und Erlotinib werden immer häufiger eingesetzt bei PatientInnen mit verschiedenen bösartigen Tumoren (u.a. von Lunge, Niere oder Bauchspeicheldrüse). Ein ungelöstes Problem ist die grosse Variabilität der indivi...
Clinical Studies - Jan 15, 2012 - Jul 31, 2015
Automatically Closed
Project leader: Jörger Markus
Members: Rothermundt Christian, Gillessen Sommer Silke, Früh Martin, Siano Marco
A randomized, double-blind, placebo-controlled multi-center study of BYM338 for treatment of cachexia in patients with stage IV non-small cell lung cancer or stage III/IV adenocarcinoma of the pancreas - EKSG 11/084
Jan 9, 2012Ein ungewollter Gewichtsverlust (Kachexie) ist bei vielen Krebsformen ein unabhängiges Anzeichen für ein kürzeres Gesamtüberleben, selbst vor Beginn einer Chemotherapie. Patienten mit Gewichtsverlust entwickeln zudem häufig stärkere Nebenwirkungen wä...
Clinical Studies - Jan 9, 2012 - Jul 31, 2012
Completed
Project leader: Strasser Florian
Members: Jörger Markus, Gueller Ulrich, Wilm Simone
Pleural pharmacokinetics of moxifloxacin and amoxicillin-clavulanate in the context of parapneumonic pleural effusions and empyema
Dec 1, 2011The main objective of the study is the characterization of the PK profiles of moxifloxacin and amoxicillin clavulanate in the pleural fluid of patients with parapneumonic effusions using population PK-analysis. Intra- and interpatient variability wil...
Clinical Studies - Dec 1, 2011 - Dec 31, 2012
Completed
Project leader: Brutsche Martin
Members: Boggian Katia, Jörger Markus, Baty Florent, Ruedlinger Luzia
An open-label, randomized, parallel group study of patients treated with Paclitaxel with standard dosing versus pharmacokinetic guided dose adjustment in patients with advanced NSCLC
Aug 10, 2011Dies ist eine offene, randomisierte, multizentrische Studie im Parallelgruppendesign, die evaluieren soll, ob eine individuell angepasste Dosierung von Paclitaxel (Arm B) Paclitaxel abhängige Grad 4 Neutropenie reduziert im Vergleich zur konventionel...
Clinical Studies - Aug 10, 2011 - Jun 30, 2012
Completed
Project leader: Jörger Markus
Members: Früh Martin, Siano Marco